ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1092

Altered Metabolic Pathways in Synovial Fibroblasts of Individuals at Risk of Developing Rheumatoid Arthritis
Abstract Number: 1093

Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Abstract Number: 1094

Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis
Abstract Number: 1095

Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression
Abstract Number: 1096

CSF-specific CD8 T Cell Clonal Expansion in Neurosarcoidosis
Abstract Number: 1097

Gastrointestinal Malignancies in Sarcoidosis: A Nationwide Analysis
Abstract Number: 1098

Does Cancer Masquerade as Sarcoidosis?
Abstract Number: 1099

Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Abstract Number: 1100

Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: A Case Series of 13 Patients
Abstract Number: 1101

Atypical Pulmonary Radiographic Findings May Help Identify Patients with Usual Interstitial Pneumonia and Autoimmune Features
Abstract Number: 1102

Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
Abstract Number: 1103

Disease Associations with Very High Serum IgG4 Concentrations: A Retrospective Multi-Center Study
Abstract Number: 1104

Pathogenic UBA1 Variants in Japanese Patients with Relapsing Polychondritis
Abstract Number: 1105

Discovering Variants in Suspected Monogenic Systemic Inflammatory Disease: An Adult Case Series
Abstract Number: 1106

Phenotypes and Genotypes of NLRP3-AID in Chinese Adult Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].